Compare Abeona Therapeutics Inc (ABEO) vs InMode Ltd (INMD) Price & Performance

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

INMD trades at $14.60, down 1.35% on the day, with mixed technical signals showing bullish moving averages but neutral oscillators. The company maintains strong profitability with 77.84% gross margins and 23.27% net income margins, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited buyout proposal at $16.20 per share and multiple securities fraud investigations announced in early July 2026.

The stock appears undervalued with a P/E of 10.81 and EV/EBITDA of 3.81, but faces near-term headwinds from legal investigations and earnings volatility. Analyst consensus sits at Hold with a $16.50 price target, representing 13% upside potential from current levels, though the ongoing legal scrutiny creates uncertainty for investors.